A mutation-defined approval
The U.S. Food and Drug Administration approved Genentech's oral estrogen-receptor antagonist giredestrant, sold as Wilserdly, in combination with everolimus on November 16. The indication covers adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease recurred during or after adjuvant endocrine therapy or progressed after endocrine treatment in the metastatic setting.[1]
Randomized evidence supports the decision
The evERA Breast Cancer trial randomized 373 adults to giredestrant or the physician's choice of exemestane, fulvestrant or tamoxifen; both groups also received everolimus. Among 207 participants with qualifying ESR1 mutations, median progression-free survival was 10 months with giredestrant and 5.5 months with the comparator. The hazard ratio was 0.38, and objective response rates were 27% and 14%, respectively.[1]
Testing becomes part of treatment
The FDA also authorized FoundationOne Liquid CDx as the companion diagnostic used to identify eligible ESR1 mutations in circulating tumor DNA. Commercial adoption therefore depends not only on drug access but also on mutation testing at the relevant stage of disease. The review was conducted through Project Orbis with Health Canada and Israel's Ministry of Health, although their decisions were not necessarily complete at the U.S. cutoff.[1]
Benefits and limits
Overall-survival results were immature when progression-free survival was analyzed, so the trial does not yet establish a survival advantage. Common adverse reactions included stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis and nausea; the label also carries precautions for bradycardia and embryo-fetal toxicity. The approval is therefore a meaningful treatment expansion rather than evidence of a cure, and comparative cost and real-world tolerability remain open questions.[1]
Sources & evidence
- FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer (opens in a new tab)U.S. Food and Drug AdministrationSource language en
The indication, companion diagnostic, trial design, efficacy results, adverse reactions and regulatory pathway.
Source note
Official public full text. A single authoritative source is used because this is a narrowly defined regulatory decision.